Novo Nordisk

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
47,792
Employees47,792
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
47,792
Employees47,792

NVO Key Statistics

Market cap
217.15B
Market cap217.15B
Price-Earnings ratio
29.22
Price-Earnings ratio29.22
Dividend yield
1.16
Dividend yield1.16
Average volume
1.23M
Average volume1.23M
High today
$96.71
High today$96.71
Low today
$95.03
Low today$95.03
Open price
$95.91
Open price$95.91
Volume
1.53M
Volume1.53M
52 Week high
$122.16
52 Week high$122.16
52 Week low
$91.51
52 Week low$91.51

NVO News

Benzinga 5h
Ominous Death Cross Forms On Novo Nordisk's Chart

If history is any guide, there may be trouble ahead for shares of Novo Nordisk NVO. A so-called "death cross" has formed on its chart and, not surprisingly, thi...

Ominous Death Cross Forms On Novo Nordisk's Chart
Simply Wall St 4d
Individual investors among Novo Nordisk A/S' (CPH:NOVO B) largest stockholders and were hit after last week's 3.4% price drop - Simply Wall St

A look at the shareholders of Novo Nordisk A/S ( ) can tell us which group is most powerful. We can see that individual investors own the lion's share in the co...

Individual investors among Novo Nordisk A/S' (CPH:NOVO B) largest stockholders and were hit after last week's 3.4% price drop - Simply Wall St
Benzinga 4d
Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec

by Novo Nordisk A/S NVO presented new data from the phase 3a ONWARDS 2 trial of insulin icodec in type 2 diabetes at the European Association for the Study of...

Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec

Analyst ratings

61%

of 28 ratings
Buy
60.7%
Hold
28.6%
Sell
10.7%

NVO Earnings

$0.00
$0.31
$0.63
$0.94
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Available Nov 2, Pre-Market
ActualAvailable Nov 2, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.